BIND Therapeutics: JMP Securities Healthcare Conference (BIND Therapeutics) - Jul 11, 2014 - Anticipated initiation of 20 patient open label trial in KRAS mutant NSCLC in Q3 2014; Anticipated trial completion for P2 trial in 2nd line (docetaxel naive) NSCLC in Q3 2014; Anticipated P2 data for 2nd line (docetaxel naive) NSCLC in Q4 2014; Anticipated P3 trial initiation for 2nd line (docetaxel naive) NSCLC in Q1 2015; Anticipated trial completion for P2 trial for 1st line (chemotherapy naive) mCRPC in H2 2014; Anticipated P2 data for 1st line (chemotherapy naive) mCRPC in Q4 2014; Anticipated P3 trial initiation for 1st line (chemotherapy naive) mCRPC in Q1 2015
Anticipated new P3 trial • Anticipated P2 data • Anticipated trial completion date • Anticipated trial initiation date • Non Small Cell Lung Cancer • Oncology • Prostate Cancer
|